Cayman 19-Noretiocholanolone; Purity- Greater Than Or Equal To 98

INDIGOs Hippo pathway assay system utilizes proprietary human cells engineered to provide high-level expression of a hybrid form of the Human Transcriptional Enhanced Associate Domain 4 Protein (TEAD4), whereby the DNA binding domain (DBD) of the native TEAD4 has been substituted with that of the yeast Gal4-DBD. Additionally, these reporter cells express the requisite transcriptional co-activator Human Yes-Associated Protein 1 (YAP) as well as the luciferase reporter gene functionally linked to tandem Gal4 Upstream Activation Sequence (UAS) genetic response elements. The use of a hybrid Gal4(DBD)-TEAD4 is a well-used strategy, and ensures that any treatment-induced changes in reporter gene activity are the direct result of changes in Gal4(DBD)-TEAD4/YAP transcriptional activity.

To reiterate, the reporter cells provided in INDIGOs assay present the "Hippo Off," or oncogenic pathway. Specifically, the Gal4(DBD)-TEAD4 transcription factor and the YAP co-activator are over-expressed to produce a constitutively active transcription complex that delivers high-level expression of the luciferase reporter gene. The primary application of this assay system is to screen test materials for inhibitory activities against the TEAD4/YAP transcription complex.

Reporter Cells are transiently transfected and prepared as frozen stocks using INDIGOs proprietary CryoMite^™ process. This cryo-preservation method allows for the immediate dispensing of healthy, division-competent reporter cells into assay plates. There is no need for cumbersome intermediate treatment steps such as spin-and-rinse of cells, viability determinations, or cell titer adjustments prior to assay setup.[INDIGO Catalog Nos. IB16001, IB16001-32, IB16002]

WARNING This product is not for human or veterinary use.